Richmond Hill, Ontario and La Jolla, CA (PRWEB) November 29, 2005
Phoenix Biomolecular Corporation today announced Dr. Michael Fossel as a member of its Science Advisory Board. Dr. Fossel is one of the leaders in the field of telomere science and human aging research worldwide. He is past Editor-in-Chief of the Journal of Anti-Aging Medicine (renamed Rejuvenation Research); Professor of Clinical Medicine at Michigan State University; recipient of a National Science Foundation Fellowship; author of the text “Cells, Aging, and Human Disease,” Oxford University Press, 2004; author of the book “Reversing Human Aging,” William Morrow, 1996; and has published numerous reports and review articles in the scientific literature, including the Journal of the American Medical Association. He received his MD and a PhD in neurobiology, both from Stanford University.
“Michael has led the way in our field since the 1990’s, consolidating the early research into telomere science, and how humans age at the cellular level,” said Douglas Coyle, Phoenix’s CEO. “Michael was the first scientist we consulted with in 2003 to determine if there were other organizations working on our approach to telomere therapy for human anti-aging. Happily, we learned that Phoenix was alone in focusing on this particular approach, and as a result Phoenix was able to acquire the exclusive rights to patents for key technology from the University of California. I am looking forward to his continued input and insight as a Phoenix Science Advisor.”
Dr. Fossel’s 1996 book Reversing Human Aging, which suggested that “telomere therapy will be available for extending your life span between 2005 and 2015”, created a great deal of controversy at the time. However, continued advances in our knowledge of human cellular biology and experimental evidence have supported many of the predictions made in the book. For example, it is now common practice to use telomere therapy to rejuvenate human cell lines for use in cell therapies. And in the lab, telomere therapy is now used to rejuvenate old skin cells to grow new patches of young skin for transplant onto animals.
“A seventy-year-old patient with bits of young skin is only the first step,” says Coyle. “The challenge is to demonstrate telomere therapy for tissues inside a living human body. Dr. Fossel’s advisory role will help Phoenix in its plans to demonstrate that telomere therapy can prevent and reverse many aspects and many diseases of human aging.”
About Phoenix: Phoenix is an early stage biotech company with anti-aging technology that, once proven, will offer the ability to rejuvenate the cells of a living human body -- with the potential to end some or all of the diseases of aging that plague us today. The core technology, called telomere therapy, has already been shown to work in repeated experiments in animals and humans for cells treated outside of the body. Phoenix expects to demonstrate that telomere therapy will also work safely and effectively when delivered to cells within a living body. Phoenix plans to use its exclusive, patent pending delivery technology to demonstrate telomere therapy and cellular rejuvenation in living animals and humans, topically for skin treatment, and internally.
Phoenix has signed an exclusive license to patents from a leading biotech lab at the University of California at San Diego (UCSD).
Phoenix has attracted the interest and participation of top-level scientists in the field, as well as institutional support. The company has secured fully equipped labs in La Jolla, California, close to UCSD, and plans to begin operations there in the first quarter of 2006.
In addition, the Phoenix delivery technology is itself a platform technology that can be used for delivering a wide range of large biomolecules to treat aging, cancer, viral, bacterial and parasitic diseases, obesity, genetic diseases and many other conditions. The potential to alleviate human suffering and the potential for financial success is unprecedented.
Phoenix is a private Delaware corporation, and is currently in discussions with private equity sources to further fund its development program.
Press Contact: Douglas Coyle, CEO? Phoenix Biomolecular Corporation
Toronto, ON: 905-883-7800 Email: firstname.lastname@example.org
San Diego, CA: 858-964-3386 Website: http://www.phoenixbiomolecular.com
Risks and Uncertainties - Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Phoenix Biomolecular Corporation, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
# # #